Skip to main content
Download PDF

Zika virus infection in Malaysia: an epidemiological, clinical and virological analysis

BMC Infectious Diseases volume 19, Article number: 152 (2019) Cite this article

Abstract

Background

A major outbreak of the Zika virus (ZIKV) has been reported in Brazil in 2015. Since then, it spread further to other countries in the Americas and resulted in declaration of the Public Health Emergency of International Concern (PHEIC) by World Health Organization. In 2016, Singapore reported its first minor ZIKV epidemic. Malaysia shares similar ecological environment as Brazil and Singapore which may also favor ZIKV transmission. However, no ZIKV outbreak has been reported in Malaysia to date. This study aimed to discuss all confirmed ZIKV cases captured under Malaysia ZIKV surveillance system after declaration of the PHEIC; and explore why Malaysia did not suffer a similar ZIKV outbreak as the other two countries.

Methods

This was an observational study reviewing all confirmed ZIKV cases detected in Malaysia through the ZIKV clinical surveillance and Flavivirus laboratory surveillance between June 2015 and December 2017. All basic demographic characteristics, co-morbidities, clinical, laboratory and outcome data of the confirmed ZIKV cases were collected from the source documents.

Results

Only eight out of 4043 cases tested positive for ZIKV infection during that period. The median age of infected patients was 48.6 years and majority was Chinese. Two of the subjects were pregnant. The median interval between the onset of disease and the first detection of ZIKV Ribonucleic Acid (RNA) in body fluid was 3 days. Six cases had ZIKV RNA detected in both serum and urine samples. Phylogenetic analysis suggests that isolates from the 7 cases of ZIKV infection came from two clusters, both of which were local circulating strains.

Conclusion

Despite similar ecological background characteristics, Malaysia was not as affected by the recent ZIKV outbreak compared to Brazil and Singapore. This could be related to pre-existing immunity against ZIKV in this population, which developed after the first introduction of the ZIKV in Malaysia decades ago. A serosurvey to determine the seroprevalence of ZIKV in Malaysia was carried out in 2017. The differences in circulating ZIKV strains could be another reason as to why Malaysia seemed to be protected from an outbreak.

Peer Review reports

Background

Zika virus (ZIKV) is an emerging mosquitoes-borne flavivirus which was first discovered in the Zika forest of Uganda in 1947 [1]. Since then, only intermittent human cases were reported in Asia and Africa; until 2007, when a major epidemic occurred on Yap Island in the Federated States of Micronesia [2, 3]. The infections then shift eastward to French Polynesia and other Pacific Islands in 2013–2014 [1, 4], reached Brazil in 2015 [5, 6], and dispersed further to other countries in South America [7]. As of 2016, ZIKV has spread much further to the North Americas and Asia [1, 7, 8].

On 1st February 2016, World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) over major worries regarding an association between the ZIKV disease and microcephaly and other neurological disorders in the epidemic region of Latin America and the Pacific Islands [9]. Subsequently, the Ministry of Health (MoH) Malaysia introduced precautionary measures against ZIKV, which includes establishing clinical and laboratory surveillance of Zika infection as well as enhancing vector control activities and crisis response towards imported cases.

In Malaysia, the ZIKV has been isolated in Aedes aegypti mosquitoes in 1966 [10]. It is the same vector which transmits other flaviviruses such as dengue, Japanese Encephalitis and Yellow Fever. Dengue virus and ZIKV are antigenically related flaviviruses that elicit similar T-cell responses and antibodies that could cross react with each other [11,12,13,14]. Some studies suggested that previous dengue infection may provide protection against ZIKV [15, 16]. Having said that, Brazil with a background dengue seroprevalence ranging from 48.4 to 97.8% among adults aged 18–65 years [17], was badly affected by ZIKV infection in 2015 [5, 6]. Singapore, another dengue endemic country also reported a minor ZIKV epidemic in 2016 although its magnitude was much smaller compared to the outbreak in Brazil [18, 19]. Similar to as Brazil and Singapore, Malaysia is hyperendemic with dengue [20] and has favourable ecological conditions for transmission of ZIKV. However, no ZIKV outbreaks have been reported in Malaysia so far.

Till date, there are no local comprehensive reports on the systematic surveillance of ZIKV are available. Surveillance efforts for ZIKV were increased in Malaysia from September 2016 after the declaration of PHEIC by the WHO in February 2016. This study aims to report epidemiological, virological and clinical findings related to the Zika infection cases detected between June 2015 and December 2017. This study also intends to discuss the situation of ZIKV transmission observed in Malaysia compared to other dengue-endemic countries such as Brazil and Singapore.

Methods

Study setting and populations

This was an observational study, which reviewed all confirmed ZIKV cases detected in Malaysia through ZIKV clinical surveillance and Flavivirus laboratory surveillance between June 2015 and December 2017. In the ZIKV clinical surveillance, clinically suspected ZIKV cases would be notified and had their blood and/or urine specimens sent to nearby listed public or private laboratory for real-time reverse transcription polymerase chain reaction (rRT-PCR). The presence of ZIKV antibodies was tested using the following commercial kits: Anti-Zika Virus IgG ELISA (Euroimmun, Germany) and ZIKV Detect™ IgM Capture ELISA (InBios, Seattle, WA, USA). All ZIKV IgM / IgG positive cases were also tested for dengue cross-reactivity using Anti-Dengue Virus IgG ELISA (Euroimmun, Germany) and DENV Detect™ IgM Capture ELISA (InBios, Seattle, WA, USA).

The Flavivirus laboratory surveillance was established since December 2015 [21]. In this surveillance, five cases will be sampled randomly each week from each sentinel site and had their serum specimens sent to the National Public Health Laboratory (NPHL) to test for Flaviviruses (dengue, Japanese encephalitis, West Nile Virus, Yellow fever, ZIKV, Bagaza virus and Usutu virus) and Chikungunya virus. The sampled cases must present to the sentinel sites within 5 days of illness onset, with signs and symptoms similar to dengue and tested negative for dengue non-structural protein-1 (NS1).

The list of confirmed ZIKV cases was obtained from the Vector Borne Disease Control Division, MoH Malaysia. All basic demographics, co-morbidities, clinical, laboratory and outcome data of the confirmed ZIKV cases were collected from the source documents, which included the medical records as well as investigational and laboratory reports. The Medical and Research Ethics Committee (MREC) from Ministry of Health (MOH) approved the study (NMRR-16-1718-32,614).

Case definition

Suspected case of ZIKV infection is defined as patient who had recent history of travelling to country or geographical area with known local ZIKV transmission (within 1 week prior to disease onset) or residing in the affected area or history of contact with a confirmed ZIKV case; and presented with rash (usually pruritic and maculopapular) and at least two or more of the following: fever, arthralgia, arthritis / periarticular oedema, or conjunctivitis (non-purulent/hyperemic) [22]. This definition was adapted from the case definition used by the Pan American Health Organization (PAHO) and WHO regional office for the Americas [23]. On the other hand, a confirmed case of ZIKV infection is defined as patient who meets both the criteria for a suspected case and has ZIKV ribonucleic acid (RNA) detected in blood and/or urine samples through rRT-PCR [22].

Phylogenetic analysis

The rRT-PCR method was adapted from Lanciotti et al. (2007) with some modifications [3]. Strains from all positive cases were then sequenced using Sanger sequencing for genomic material characterization. The chromatograms were analysed using ChromPro (Version 2.0) software. The alignment was carried out using Molecular Evolutionary Genetics Analysis (MEGA version 5.05) while phylogenetic tree was generated using the Clustal X software. The sequences were searched using Basic Local Alignment Search Tool (BLAST) and deposited in the GenBank with accession numbers KX906953.1, KX906955.1, KX906954.1, MH130043.1, MH130044.1, KX906956.1 and MH130042.1.

Statistical analysis

Data were compiled and analyzed using Microsoft Excel 2017. All data were anonymized during analysis. Descriptive analysis was done to describe background characteristics, clinical presentations, laboratory findings and clinical outcome of the included cases. All categorical variables were presented as frequencies and percentages; while continuous variables were presented in median and interquartile range.

Results

Demographic profiles

A total of 250 cases fulfilled the case definition and were notified and screened for ZIKV infection through the ZIKV clinical surveillance [24]. After laboratory testing, only seven cases were confirmed as ZIKV infection. Also, 3793 cases were tested for ZIKV infection through the Flavivirus laboratory surveillance and only one case was detected positive for ZIKV. For the remaining cases, 2139 (56.4%) tested positive for dengue, 1517 (40%) were negative for Flaviruses and 136 (3.6%) tested positive for Chikungunya. These eight confirmed ZIKV cases detected through both surveillance programs were included for further discussion in this study (Table 1). As part of public health efforts to control ZIKV transmission, active case detection was conducted subsequently within 400 m from the index cases. Total of 2767 cases were screened in active detection but all samples tested negative.

Table 1 Demographic Profile of Confirmed ZIKV Cases in Malaysia
Full size table

Patients’ ages ranged between 25 and 61 years, with a median of 48.6 years. Most of the patients were Chinese. All patients were discharged well from health care facilities except a male patient who succumbed to acute myocardial infarction with myocarditis. The patient also had underlying Zika and dengue virus co-infection, in which the dengue infection was confirmed by Multiplex dengue real time RT-PCR. Out of five females with confirmed ZIKV infection, two of them were pregnant at 10 and 17 weeks of gestation respectively. One of the pregnant women was lost to follow-up while the other delivered a baby at term without congenital Zika syndrome. At birth, the newborn’s serum and urine tested negative for ZIKV based on rRT-PCR. During a 2-year follow-up period, clinical and developmental assessments revealed normal development. Findings from ophthalmology examination by fundoscopy, hearing assessment by auditory brainstem response and neuro-imaging by cranial ultrasound were unremarkable.

Clinical presentation

Rash was the most common clinical manifestation, which was observed in nearly all patients, followed by fever and myalgia (Table 2). None of the patients had headache upon presentation and only one patient complained of conjunctivitis.

Table 2 Clinical Presentation of Confirmed ZIKV Cases in Malaysia
Full size table

Laboratory findings

Eight cases were confirmed with ZIKV infection based on the detection of ZIKV genome in body fluids by rRT-PCR. The median duration between onset of disease and first detection of ZIKV genome in body fluids was 3 days (IQR: 3, 4.5). Six out of eight cases had ZIKV RNA detected in both serum and urine samples; but other two patients had ZIKV RNA detected in either serum or urine samples only (Table 3). In addition, five of the confirmed ZIKV cases also had evidence of ZIKV immunoglobulin M (IgM), indicating recent infection. Median time to detection of ZIKV IgM was 5 days (IQR: 4, 6). Although ZIKV IgG was detected in the five cases, there was also evidence of cross reactivity between Zika and Dengue IgG antibodies [13, 25, 26]. Median time to detection of ZIKV IgG was 4 days (IQR: 4, 5.5).

Table 3 Summary of Laboratory Findings of Confirmed ZIKV Cases
Full size table

In terms of phylogenetic analysis, only a 574 base pair (bp) fragment of the envelope gene of the virus were successfully sequenced due to low copy number of the virus from the study subjects. The results indicate that there are two clusters of ZIKV strains where two strains (MyH318 and MyH326) had clustered with strains from Singapore (2016) while the remaining five strains (MyH319, MyH349, MyH414, MyH334 and MyH335) were clustered into another group which includes older ZIKV strains such as the Micronesian (2007) and Cambodian (2010) strains (Fig. 1).

Fig. 1
figure 1

Phylogenetic tree of partial envelope gene (574 bp) of the Zika virus. The tree was inferred using the Neighbor-Joining method [62]. The tree was drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Maximum Composite Likelihood method [63] and were in the units of the number of base substitutions per site. The analysis involved 36 nucleotide sequences. Evolutionary analyses were conducted in MEGA5.05 [64]

Full size image

Discussion

Clinical features & laboratory findings

Generally, the ZIKV infection can produce diverse clinical symptoms in humans, ranging from asymptomatic presentation to flu-like symptoms [1, 27, 28]. The common symptoms associated with the ZIKV infection include fever, rash, non-purulent conjunctivitis, arthritis and arthralgia [29, 30]. This is reflected in our study where most of the patients complained of fever upon presentation. As rash was one of the mandatory criteria for ZIKV screening in clinical surveillance, all cases included in this study complained of rashes except one which was detected through the Flavivirus laboratory surveillance.

As compared to other modes of detection, rRT-PCR is the most common method used in diagnosing ZIKV infection because of its specificity and ability in differentiating ZIKV from other flavivirus infections [31]. However, rRT-PCR on serum sample is found to have lower sensitivity owing to low and short duration of viremia in humans [32]. Previous literature suggested detection of higher viral RNA load in urine samples for longer duration [33, 34], therefore it is recommended to perform rRT-PCR on both blood and urine samples in order to increase test sensitivity, particularly during the late stage of infection [35]. In this study, both serum and urine samples were tested for ZIKV genome. The detection rate of ZIKV RNA in both serum and urine samples were similar.

Phylogenetic analysis

Phylogenetic analysis was conducted to determine genetic relationship among all ZIKV strains detected in 2016 as well as with the 1966 ZIKV strain from Bentong, Malaysia. Interestingly, two Malaysian strains (MyH318 and MyH326) had clustered with strains from Singapore (2016) and were from patients with history of travel to Singapore. On the other hand, all the remaining five Malaysian strains (MyH319, MyH349, MyH414, MyH334 and MyH335) were clustered with the Micronesian (2007) strain, and came from patients with no history of recent travel. This indicated that they were all infected with locally circulating ZIKV strains. These findings are important as it provides evidence that ZIKV is circulating amongst our population and there are possible risks to pregnant women and their babies.

Public health measures taken to detect and contain ZIKV transmission

The detection rate of ZIKV infection among cases which were tested for ZIKV infection was 0.2%. The index cases were sporadic and no ZIKV outbreak was observed during the study period. This observation could be attributed to measures taken by MoH Malaysia after declaration of PHEIC. According to the standard operating procedure [22], once a confirmed Zika case was reported, the district health office has to conduct active case detection towards household members and close contacts of the index cases, as well as any households within a 400 m radius from the index case that have any signs and symptoms of ZIKV infection. All cases would have their blood and urine samples taken for confirmation of ZIKV infection.

During active case detection, the Malaysian Public Health Division also incorporated a series of control and preventive strategies to contain ZIKV transmission from the index cases. These include source reduction, larviciding, fogging and ultra-low volume (ULV) spray within a 400 m radius from the index case. These measures were taken within 24 h after the notification of index cases, which could potentially contain the ZIKV transmission from index cases.

Comparison of ZIKV infection in Malaysia with Brazil and Singapore

In 2015, Brazil reported its first autochthonous transmission of ZIKV [5, 6]. It caused an epidemic of ZIKV in at least 14 Brazilian states, with an estimated 440,000 to 1,300,000 suspected ZIKV cases being reported [7]. Since then, ZIKV has spread at an alarming rate throughout Central and South America and the Caribbean [1, 7, 8]. Following this outbreak, Malaysia has also reported its first autochthonous Zika case in September 2016.

ZIKV infection in Malaysia was not as widespread compared to the outbreaks in neighbouring countries such as Singapore and Thailand [36]. The incidence of ZIKV infection in Singapore and Thailand was about 0.81 and 0.16 per 10,000 population respectively in year 2016 [18, 37], as compared to Malaysia where the incidence was less than 0.01 per 10,000 population. Overall, there were only eight clinical cases of Zika as most cases of Zika would have been missed due to the asymptomatic nature of the infection. Unlike the dengue virus with four different serotypes, previous infection of ZIKV provides protection against re-infection of ZIKV [38]. Hence, among possible reasons, it could be the higher seroprevalence of Zika in Malaysia that makes clinical cases of Zika uncommon. This assumption is based on the history of Zika in Peninsular Malaysia, which started in the 1960s when the virus was isolated from Aedes aegypti mosquitoes in Bentong, Pahang [10]. Another ZIKV seroprevalence study by Wolfe ND et al. showed that 44.1% of the local study population in 1996–1997 were sero-positive for ZIKV [39]. Subsequently, the only other clinical case of Zika was reported in a German tourist who visited Sabah in 2014 [40]. Based on this evidence, it is highly likely that ZIKV has been circulating in the Malaysian population for decades. Because of this, the community would have been provided a respite from large Zika outbreaks. However, whether this also translates into protection against fetal abnormalities needs further research.

Although our phylogenetic analysis showed that the cases of ZIKV detected in Malaysia during 2016 originated from two different sources, it appears that all the isolates were closely related to the old ZIKV strains that have been circulating in South East Asia. On the other hand, studies have shown that the South American ZIKV isolates formed a unique clade within the Asian lineage, which was also demonstrated in our study [41, 42]. Current literature suggested that the American strain of ZIKV seemed to transmit the virus more efficiently through Aedes aegypti [43], and resulted in more serious brain damage in mice as compared to other old Asian strain of ZIKV [44]. This difference of the circulating ZIKV strains could be another explanation as to why Malaysia was not as badly affected by the recent ZIKV outbreak in Brazil.

On the other hand, questions arise to why ZIKV transmission in Malaysia does not seem to be as pervasive as in the neighbouring nation, Singapore although both countries are similar in terms of its ecological environment and circulating ZIKV strains [45]. Singaporean authorities reported a total of 455 cases of ZIKV infection within 3 months in 2016 [18] compared to the eight cases in Malaysia in the same year. The explanation for this observation remains unclear, but one theory is that Singaporean population may have a lower prevalence of immunity towards ZIKV infection than Malaysia. Also, transmission of ZIKV is partially dependent on its vector population. Comparatively, Singapore has a smaller Aedes mosquito population [46,47,48,49]; which may result in a low transmission setting and subsequently give rise to population with low background immunity against ZIKV.

In addition, being a city-state with very small land size compared to Malaysia, Singapore is able to conduct more extensive active case detection, contact tracing, disease surveillance and education of public and health care professionals; which may have contributed to the higher pick up rate of sub-clinical ZIKV cases. Another postulation for the difference in case detection between Malaysia and Singapore could be attributed to the low perception of disease severity among Malaysian. About half of Malaysians surveyed do not consider that Malaysia at risk of ZIKV transmission [50], and a study proved that community-based mosquito control practices did not differ before and after declaration of PHEIC by WHO [51].

Strengths and limitations

This study discussed all confirmed ZIKV cases captured under the Malaysian ZIKV clinical surveillance and Flavivirus laboratory surveillance. All cases notified to the Malaysian ZIKV clinical surveillance system had both blood and urine samples tested with rRT-PCR for confirmation of ZIKV infection. Although the duration of detectable ZIKV RNA in serum is relatively short, studies had shown ZIKV RNA remain detectable in urine for a longer duration after becoming undetectable in the serum [33, 35, 52, 53]. Because patients sought medical attention while they still had symptoms, it is unlikely that screening of both serum and urine samples would miss out on positive cases of ZIKV infection. In addition, this study also explored why Malaysia did not experience an outbreak to the scale of those observed in Brazil and Singapore although all three countries are dengue-endemic countries and share similar ecological environments.

However, this study is limited by a few limitations. Firstly, the rRT-PCR assay used for the detection of ZIKV infection was adapted from Lanciotti et al. (2007), which its primer sets were designed based on the sequence of ZIKV population in Africa and South America [3]. Therefore, there is concern with its ability to amplify the ZIKV population in Southeast Asia (SEA). However, previous validation studies had reported the high analytical sensitivity of this assay in detecting both African and Asian lineage [54, 55]. Secondly, we were unable to sequence the whole viral genome, hence the partial E region rather than the whole genome was used for phylogenetic analysis. This could possibly result in discrepancy between our phylogenetic tree compared to one which uses the whole genome. However, many published studies also used the partial E region for phylogenetic analysis of the ZIKV [42, 56, 57]. Thirdly, we acknowledge the possible misdiagnosis or under-detection of ZIKV infection for patients who did not fulfill the screening criteria. In this study, we adapted the case definition used by PAHO and WHO regional office for the Americas, in which rash is one of the mandatory criteria for ZIKV screening. Although rash is one of the most common symptoms among ZIKV patients, published literature reported its prevalence to vary between 77 and 100% [2, 18, 27, 58,59,60]. Therefore, we could potentially miss out some cases which did not present with rash. Lastly, the ZIKV clinical surveillance system in Malaysia is mainly passive where its reporting system is solely dependent on notification by health care providers. Active ZIKV case detection only takes place during the process of contact tracing after an index case has been identified. Hence, there is a possibility of under-reporting as majority of cases were sub-clinical [1], and patients may not seek for medical attention if it was a mild disease.

Conclusion

This study summarized all ZIKV cases detected in Malaysia after declaration of PHEIC by WHO. Despite similar background characteristics, Malaysia was not affected by ZIKV as much as Brazil and Singapore. This could be related to the development of immunity against ZIKV in the population due to the introduction of ZIKV in Malaysia decades ago. This hypothesis will soon be answered by a study conducted by MOH Malaysia which investigated ZIKV seroprevalence in Malaysia. The local circulating ZIKV strains is different from the South American cluster, which could possibly explain why Malaysia seemed to be protected from a ZIKV outbreak.

Abbreviations

BLAST:

Basic Local Alignment Search Tool

DENV:

Dengue virus

IgG:

Immunoglobulin G

IgM:

Immunoglobulin M

MOH:

Ministry of Health

MREC:

Medical Research Ethics Committee

NMRR:

National Medical Research Register

PAHO:

Pan American Health Organization

PHEIC:

Public Health Emergency of International Concern

RNA:

Ribonucleic Acid

rRT-PCR:

Real-time Reverse Transcription Polymerase Chain Reaction

SEA:

Southeast Asia

WHO:

World Health Organization

ZIKV:

Zika Virus

References

  1. Song BH, Yun SI, Woolley M, Lee YM. Zika virus: history, epidemiology, transmission, and clinical presentation. J Neuroimmunol. 2017;308:50–64.

    Article  CAS  Google Scholar 

  2. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick M, Marfel M, Holzbauer S, Dubray C, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536–43.

    Article  CAS  Google Scholar 

  3. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, Stanfield SM, Duffy MR. Genetic and serologic properties of Zika virus associated with an epidemic, yap state, Micronesia, 2007. Emerg Infect Dis. 2008;14(8):1232–9.

    Article  CAS  Google Scholar 

  4. Ioos S, Mallet HP, Leparc Goffart I, Gauthier V, Cardoso T, Herida M. Current Zika virus epidemiology and recent epidemics. Med Mal Infec. 2014;44(7):302–7.

    Article  CAS  Google Scholar 

  5. Campos GS, Bandeira AC, Sardi SI. Zika Virus Outbreak, Bahia, Brazil. Emerg Infect Dis. 2015;21(10):1885–6.

    Article  Google Scholar 

  6. Zanluca C, Melo VC, Mosimann AL, Santos GI, Santos CN, Luz K. First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz. 2015;110(4):569–72.

    Article  CAS  Google Scholar 

  7. Hennessey M, Fischer M, Staples JE. Zika virus spreads to new areas - region of the Americas, may 2015-January 2016. MMWR Morb Mortal Wkly Rep. 2016;65(3):55–8.

    Article  Google Scholar 

  8. Lim SK, Lim JK, Yoon IK. An Update on Zika Virus in Asia. Infec Chemother. 2017;49(2):91–100.

    Article  Google Scholar 

  9. WHO.: WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. . In. World Health Organization 2016.

  10. Marchette NJ, Garcia R, Rudnick A. Isolation of Zika virus from Aedes aegypti mosquitoes in Malaysia. Am J Trop Med Hyg. 1969;18(3):411–5.

    Article  CAS  Google Scholar 

  11. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Simon-Loriere E, Sakuntabhai A, Cao-Lormeau VM, Haouz A, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536(7614):48–53.

    Article  CAS  Google Scholar 

  12. Ekins S, Liebler J, Neves BJ, Lewis WG, Coffee M, Bienstock R, Southan C, Andrade CH. Illustrating and homology modeling the proteins of the Zika virus. F1000Research. 2016;5:275.

    Article  Google Scholar 

  13. Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, Pattanapanyasat K, Chokephaibulkit K, Mulligan MJ, Wilson PC, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113(28):7852–7.

    Article  CAS  Google Scholar 

  14. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, Vanzetta F, Minola A, Jaconi S, Mele F, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823–6.

    Article  CAS  Google Scholar 

  15. Swanstrom JA, Plante JA, Plante KS, Young EF, McGowan E, Gallichotte EN, Widman DG, Heise MT, de Silva AM, Baric RS. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. mBio. 2016;7(4).

  16. Wen J, Elong Ngono A, Regla-Nava JA, Kim K, Gorman MJ, Diamond MS, Shresta S. Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent Zika virus challenge. Nat Commun. 2017;8(1):1459.

    Article  Google Scholar 

  17. Teixeira MG, Siqueira JB Jr, Ferreira GL, Bricks L, Joint G. Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. PLoS Negl Trop Dis. 2013;7(12):e2520.

    Article  Google Scholar 

  18. Singapore Zika Study G. Outbreak of Zika virus infection in Singapore: an epidemiological, entomological, virological, and clinical analysis. Lancet Infect Dis. 2017;17(8):813–21.

    Article  Google Scholar 

  19. Fisher D, Cutter J. The inevitable colonisation of Singapore by Zika virus. BMC Med. 2016;14(1):188.

    Article  Google Scholar 

  20. iDengue [http://idengue.remotesensing.gov.my/idengue/page2.php?kandungan=content/statistik.pdf].

  21. Abdullah NH: Implementation of Flavivirus laboratory surveillance program. In. Edited by Malaysia MoH. Malaysia 2015.

  22. MOH Malaysia: "updated Zika alert" and administration directive for monitoring and management of Zika virus infection in. Edited by Malaysia MoH; 2016.

  23. Zika resources: Case definitions. [https://www.paho.org/hq/index.php?option=com_content&view=article&id=11117:zika-resources-case-definitions&Itemid=41532&lang=en].

  24. Malaysia. M: Press statement: Situation on dengue fever, chikungunya and Zika in Malaysia in 2017 In. Putrajaya, Malaysia 2017.

  25. Felix AC, Souza NCS, Figueiredo WM, Costa AA, Inenami M, da Silva RMG, Levi JE, Pannuti CS, Romano CM. Cross reactivity of commercial anti-dengue immunoassays in patients with acute Zika virus infection. J Med Virol. 2017;89(8):1477–9.

    Article  CAS  Google Scholar 

  26. Koraka P, Zeller H, Niedrig M, Osterhaus AD, Groen J. Reactivity of serum samples from patients with a flavivirus infection measured by immunofluorescence assay and ELISA. Microbes Infect. 2002;4(12):1209–15.

    Article  CAS  Google Scholar 

  27. Cerbino-Neto J, Mesquita EC, Souza TM, Parreira V, Wittlin BB, Durovni B, Lemos MC, Vizzoni A, Bispo de Filippis AM, Sampaio SA, et al. Clinical manifestations of Zika virus infection, Rio de Janeiro, Brazil, 2015. Emerg Infect Dis. 2016;22(7):1318–20.

    Article  CAS  Google Scholar 

  28. Marano G, Pupella S, Vaglio S, Liumbruno GM, Grazzini G. Zika virus and the never-ending story of emerging pathogens and transfusion medicine. Blood Transfu. 2016;14(2):95–100.

    Google Scholar 

  29. Basarab M, Bowman C, Aarons EJ, Cropley I. Zika virus. Bmj. 2016;352:i1049.

    Article  Google Scholar 

  30. Sharma A, Lal SK. Zika virus: transmission, detection, control, and prevention. Front Microbiol. 2017;8:110.

    PubMed  PubMed Central  Google Scholar 

  31. Wong SS, Poon RW, Wong SC. Zika virus infection-the next wave after dengue? J Formos Med Assoc. 2016;115(4):226–42.

    Article  Google Scholar 

  32. Vorou R. Zika virus, vectors, reservoirs, amplifying hosts, and their potential to spread worldwide: what we know and what we should investigate urgently. Int J Infect Dis. 2016;48:85–90.

    Article  Google Scholar 

  33. Jeong YE, Cha GW, Cho JE, Lee EJ, Jee Y, Lee WJ. Viral and serological kinetics in Zika virus-infected patients in South Korea. Virol J. 2017;14(1):70.

    Article  Google Scholar 

  34. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus. Emerg Infect Dis. 2015;21(2):359–61.

    Article  CAS  Google Scholar 

  35. Gourinat AC, O'Connor O, Calvez E, Goarant C, Dupont-Rouzeyrol M. Detection of Zika virus in urine. Emerg Infect Dis. 2015;21(1):84–6.

    Article  CAS  Google Scholar 

  36. Epidemiological update: Outbreaks of Zika virus and complications potentially linked to the Zika virus infection, 13 October 2016 [https://ecdc.europa.eu/en/news-events/epidemiological-update-outbreaks-zika-virus-and-complications-potentially-linked-32].

  37. Buathong R. Zika virus infection in Thailand: detect prevent respond and future research. In: Arboviruses: a global public health threat 2018; France; 2018.

    Google Scholar 

  38. Osuna CE, Lim SY, Deleage C, Griffin BD, Stein D, Schroeder LT, Omange R, Best K, Luo M, Hraber PT, et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat Med. 2016;22(12):1448–55.

    Article  CAS  Google Scholar 

  39. Wolfe ND, Kilbourn AM, Karesh WB, Rahman HA, Bosi EJ, Cropp BC, Andau M, Spielman A, Gubler DJ. Sylvatic transmission of arboviruses among Bornean orangutans. Am J Trop Med Hyg. 2001;64(5–6):310–6.

    Article  CAS  Google Scholar 

  40. Tappe D, Nachtigall S, Kapaun A, Schnitzler P, Gunther S, Schmidt-Chanasit J. Acute Zika virus infection after travel to Malaysian Borneo, September 2014. Emerg Infect Dis. 2015;21(5):911–3.

    Article  CAS  Google Scholar 

  41. Kochakarn T, Kotanan N, Kumpornsin K, Loesbanluechai D, Thammasatta M, Auewarakul P, Wilairat P, Chookajorn T. Comparative genome analysis between southeast Asian and south American Zika viruses. Asian Pac J Trop Med. 2016;9(11):1048–54.

    Article  CAS  Google Scholar 

  42. Ye Q, Liu ZY, Han JF, Jiang T, Li XF, Qin CF. Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas. Infect Genet Evol. 2016;43:43–9.

    Article  CAS  Google Scholar 

  43. Pompon J, Morales-Vargas R, Manuel M, Huat Tan C, Vial T, Hao Tan J, Sessions OM, Vasconcelos PDC, Ng LC, Misse D. A Zika virus from America is more efficiently transmitted than an Asian virus by Aedes aegypti mosquitoes from Asia. Sci Rep. 2017;7(1):1215.

    Article  Google Scholar 

  44. Zhang F, Wang HJ, Wang Q, Liu ZY, Yuan L, Huang XY, Li G, Ye Q, Yang H, Shi L, et al. American strain of Zika virus causes more severe microcephaly than an old Asian strain in neonatal mice. EBioMedicine. 2017;25:95–105.

    Article  Google Scholar 

  45. Maurer-Stroh S, Mak TM, Ng YK, Phuah SP, Huber RG, Marzinek JK, Holdbrook DA, Lee RT, Cui L, Lin RT. South-east Asian Zika virus strain linked to cluster of cases in Singapore, august 2016. Euro Surveill. 2016;21(38).

  46. Aziz S, Aidil RM, Nisfariza MN, Ngui R, Lim YA, Yusoff WS, Ruslan R. Spatial density of Aedes distribution in urban areas: a case study of breteau index in Kuala Lumpur Malaysia. J Vector Borne Dis. 2014;51(2):91–6.

    CAS  PubMed  Google Scholar 

  47. MOH Singapore: Communicable disease surveillance in Singapore 2013. In. Singapore: Ministry of Health; 2013.

  48. Ng LC, Tan HK, Tan LK, Chong CS, Ho D. Evolving dengue control programme in Singapore. Epidemiological News Bulletin Singapore. 2016;42(1):11–5.

    Google Scholar 

  49. Wan-Norafikah O, Nazni WA, Noramiza S, Shafa’ Ar-Ko'Ohar S, Heah SK, Nor-Azlina, Khairul-Asuad M, Lee HL: Distribution of Aedes mosquitoes in three selected localities in Malaysia. Sains Malaysiana 2012, 41(10):1309–1313.

  50. Arief M, Hassali MA, Saleem F, Khan MU, Ahmad A, Bhagavathulha AS, Jamshed SQ. A cross-sectional survey on the knowledge and attitudes towards Zika virus and its prevention among residents of Selangor, Malaysia. J Pharm Pract Comm Med. 2017;3(2):81–9.

    Article  Google Scholar 

  51. Wong LP, Alias H, Aghamohammadi N, Sam IC, AbuBakar S. Differences in perceived severity of Zika virus infection and dengue fever and its influence on mosquito control practices in Malaysia. J Community Health. 2017;42(5):854–64.

    Article  Google Scholar 

  52. Judice CC, Tan JJL, Parise PL, Kam YW, Milanez GP, Leite JA, Caserta LC, Arns CW, Resende MR, Angerami R, et al. Efficient detection of Zika virus RNA in patients' blood from the 2016 outbreak in Campinas, Brazil. Sci Rep. 2018;8(1):4012.

    Article  Google Scholar 

  53. Waggoner JJ, Pinsky BA. Zika virus: diagnostics for an emerging pandemic threat. J Clin Microbiol. 2016;54(4):860–7.

    Article  CAS  Google Scholar 

  54. Charrel RN, Leparc-Goffart I, Pas S, de Lamballerie X, Koopmans M, Reusken C. Background review for diagnostic test development for Zika virus infection. Bull World Health Organ. 2016;94(8):574–584D.

    Article  Google Scholar 

  55. Corman VM, Rasche A, Baronti C, Aldabbagh S, Cadar D, Reusken CB, Pas SD, Goorhuis A, Schinkel J, Molenkamp R, et al. Assay optimization for molecular detection of Zika virus. Bull World Health Organ. 2016;94(12):880–92.

    Article  Google Scholar 

  56. Faye O, Freire CC, Iamarino A, Faye O, de Oliveira JV, Diallo M, Zanotto PM, Sall AA. Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS Negl Trop Dis. 2014;8(1):e2636.

    Article  Google Scholar 

  57. Shen S, Shi J, Wang J, Tang S, Wang H, Hu Z, Deng F. Phylogenetic analysis revealed the central roles of two African countries in the evolution and worldwide spread of Zika virus. Virol Sin. 2016;31(2):118–30.

    Article  Google Scholar 

  58. Meltzer E, Leshem E, Lustig Y, Gottesman G, Schwartz E. The clinical Spectrum of Zika virus in returning travelers. Am J Med. 2016;129(10):1126–30.

    Article  Google Scholar 

  59. Ng DHL, Ho HJ, Chow A, Wong J, Kyaw WM, Tan A, Chia PY, Choy CY, Tan G, Yeo TW, et al. Correlation of clinical illness with viremia in Zika virus disease during an outbreak in Singapore. BMC Infect Dis. 2018;18(1):301.

    Article  Google Scholar 

  60. Thomas DL, Sharp TM, Torres J. Local transmission of Zika virus - Puerto Rico, November 23, 2015 - January 28, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(6):154–8.

    Article  Google Scholar 

  61. FAQ: When do I not need a patient information sheet & inform consent form (PIS/ICF)? [http://nih.gov.my/web/mrec/faqs-2/].

  62. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4(4):406–25.

    CAS  Google Scholar 

  63. Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci U S A. 2004;101(30):11030–5.

    Article  CAS  Google Scholar 

  64. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Director-General of Health, MoH Malaysia for his permission to publish this study. We would also like to acknowledge members of the Healthcare Statistics Unit, Clinical Research Centre, MoH Malaysia for their roles in data collection. We are also grateful to Dr. Giri Shan Rajahram, Dr. Kan Foong Kee, Dr. Leong Chee Loon, Dr. Marilyn Charlene Montini Maluda, Dr. Ravichandran Jeganathan, Dr. Teh Yeon Chiat, Dr. Ravichandran Jeganathan, Dr. Azirawati Johari, Dr. Masliyana Husin and other doctors with the MoH for their expert assistance in this study. The authors also wish to thank the state vector units for their support in the process of data collection.

Funding

This study was funded by the authors’ own institution which supported the conduct of the study and publication fee. The funders had no role in the study design, analysis and preparation of the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study is available from the author, Dr. Sheamini Sivasampu on reasonable request.

Author information

Authors and Affiliations

  1. Clinical Epidemiology Unit, National Clinical Research Centre, Ministry of Health Malaysia, Level 2, Block B4, National Institute of Health, Jalan Setia Murni U13/52, Seksyen U13, 40170, Shah Alam, Selangor Darul Ehsan, Malaysia

    Yuan Liang Woon

  2. Healthcare Statistics Unit, National Clinical Research Centre, Ministry of Health Malaysia, Level 4, Block B4, National Institute of Health, Jalan Setia Murni U13/52, Seksyen U13, 40170, Shah Alam, Selangor Darul Ehsan, Malaysia

    Mei Fong Lim & Sheamini Sivasampu

  3. Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, Jalan Pahang, 50588, Kuala Lumpur, Malaysia

    Tg Rogayah Tg Abd Rashid & Ravindran Thayan

  4. Department of General Medicine, Hospital Sungai Buloh, Jalan Hospital, 47000, Sungai Buloh, Selangor Darul Ehsan, Malaysia

    Suresh Kumar Chidambaram

  5. Sector of Vector-Borne Disease, Disease Control Division, Ministry of Health Malaysia, 62590, Putrajaya, Malaysia

    Syed Sharizman Syed Abdul Rahim & Rose Nani Mudin

Authors
  1. Yuan Liang Woon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mei Fong Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tg Rogayah Tg Abd Rashid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ravindran Thayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Suresh Kumar Chidambaram
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Syed Sharizman Syed Abdul Rahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rose Nani Mudin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sheamini Sivasampu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YLW, MFL, TRTAB, RT, SKC, SSSAR, RNM and SS conceived the idea for this manuscript. MFL and TRTAB carried out the data analysis and YLW wrote the first draft of the manuscript. YLW, MFL, TRTAB, RT, SKC, SSSAR, RNM and SS interpreted the results and critically reviewed drafts of this manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yuan Liang Woon.

Ethics declarations

Ethical approval and consent to participate

This study was registered under National Medical Research Register (NMRR-16-1718-32,614, NMRR-16-1840-32,813) and approved by Malaysian Medical Research Ethics Committee (MREC), MoH Malaysia. According to MREC guideline, informed consent is not needed if the study involves the collection or use of existing data and records, or if anonymity of study subjects are assured [61]. This study involved review of existing medical records and all cases were anonymized during data analysis.

Competing interest

The authors declare that they have no competing interests.

Consent for publication

This is not applicable as this manuscript does not contain any individual person’s identifiable data or information.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Woon, Y., Lim, M., Tg Abd Rashid, T. et al. Zika virus infection in Malaysia: an epidemiological, clinical and virological analysis. BMC Infect Dis 19, 152 (2019). https://doi.org/10.1186/s12879-019-3786-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-019-3786-9

Keywords

  • Zika
  • Malaysia
  • Epidemiology

BMC Infectious Diseases

ISSN: 1471-2334

Contact us